Core Viewpoint - MiRXES-B (02629) has entered into a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on the registration and commercialization of molecular diagnostic tests and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1] Group 1 - The memorandum is valid for 12 months from the date of signing [1] - The collaboration allows MiRXES to leverage PT DIASTIKA BIOTEKINDO's existing channels to enter the Indonesian market with blood-based microRNA or multi-omics cancer detection devices for prevalent cancers such as gastric and lung cancer [1] - The partnership aims to utilize local policies in Indonesia, such as tax incentives for a localization rate of 40%, and regulatory flexibility under ASEAN-centered medical device frameworks [1] Group 2 - Indonesia is viewed as a pilot region for the business, with plans to replicate operations in Southeast Asia, the Middle East, North Africa, and other regions that have similar cancer profiles and healthcare structures [1]